Related Experiment Video
Updated: Jan 27, 2026

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
Published on: May 20, 2020
CD317 Activates EGFR by Regulating Its Association with Lipid Rafts
Guizhong Zhang1, Xin Li1, Qian Chen1
1Shenzhen Laboratory of Fully Human Antibody Engineering, Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, People's Republic of China.
Abstract:
EGFR regulates various fundamental cellular processes, and its constitutive activation is a common driver for cancer. Anti-EGFR therapies have shown benefit in cancer patients, yet drug resistance almost inevitably develops, emphasizing the need for a better understanding of the mechanisms that govern EGFR activation. Here we report that CD317, a surface molecule with a unique topology, activated EGFR in hepatocellular carcinoma (HCC) cells by regulating its localization on the plasma membrane. CD317 was upregulated in HCC cells, promoting cell-cycle progression and enhancing tumorigenic potential in a manner dependent on EGFR. Mechanistically, CD317 associated with lipid rafts and released EGFR from these ordered membrane domains, facilitating the activation of EGFR and the initiation of downstream signaling pathways, including the Ras-Raf-MEK-ERK and JAK-STAT pathways. Moreover, in HCC mouse models and patient samples, upregulation of CD317 correlated with EGFR activation. These results reveal a previously unrecognized mode of regulation for EGFR and suggest CD317 as an alternative target for treating EGFR-driven malignancies. SIGNIFICANCE: Activation of EGFR by CD317 in hepatocellular carcinoma cells suggests CD317 as an alternative target for treating EGFR-dependent tumors.
Insights
CD317 activates epidermal growth factor receptor (EGFR) in liver cancer cells by altering EGFR
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- Epidermal growth factor receptor (EGFR) is crucial for cellular functions, and its overactivation drives cancer.
- Resistance to anti-EGFR therapies necessitates understanding EGFR activation mechanisms.
Purpose of the Study:
- To investigate the role of CD317 in EGFR activation within hepatocellular carcinoma (HCC).
- To elucidate the mechanism by which CD317 influences EGFR localization and activity.
Main Methods:
- Investigated CD317 expression and its correlation with EGFR in HCC cells and patient samples.
- Utilized cell-based assays to examine CD317's effect on EGFR localization within lipid rafts.
- Analyzed downstream signaling pathways (Ras-Raf-MEK-ERK, JAK-STAT) activated by CD317-mediated EGFR signaling.
- Employed HCC mouse models to validate findings in vivo.
Main Results:
- CD317 is upregulated in HCC cells and promotes cell-cycle progression and tumorigenesis dependent on EGFR.
- CD317 releases EGFR from lipid rafts, leading to EGFR activation and downstream signaling.
- CD317 upregulation correlates with EGFR activation in HCC mouse models and patient tissues.
Conclusions:
- CD317 activates EGFR in hepatocellular carcinoma by modulating its plasma membrane localization.
- CD317 represents a novel regulatory mechanism for EGFR and a potential therapeutic target for EGFR-driven cancers.
Related Concept Videos
Enteric Nervous System: Regulation of GI Motor Activity
During periods of fasting, the ENS initiates the migrating myoelectric complex, a...
GPCRs Regulate Adenylyl Cylase Activity
What are Lipids?
Co-activators and Co-repressors
Regulation of Expression Occurs at Multiple Steps
Transcription results in the generation of precursor (pre-mRNA) that consists of both exons and introns, which needs further processing before being translated to a...
GTPases and their Regulation
Large G-proteins,...

